<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582215</url>
  </required_header>
  <id_info>
    <org_study_id>SCR-005</org_study_id>
    <nct_id>NCT03582215</nct_id>
  </id_info>
  <brief_title>Assessment of the Human Systemic Absorption of Sunscreen Ingredients</brief_title>
  <official_title>Assessment of the Human Systemic Absorption of Sunscreen Ingredients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spaulding Clinical Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Food and Drug Administration (FDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the systemic exposure and pharmacokinetics of sunscreen
      active ingredients (avobenzone, oxybenzone, ecamsule, octocrylene homosalate, octisalate and
      octinoxate) when sunscreen product is applied under maximal use conditions.

      Part 1 is an open-label, randomized, 4-arm study in 24 healthy adult subjects with the
      primary objective to explore whether the active components (avobenzone, oxybenzone, ecamsule
      and octocrylene) of 4 sunscreen products (1 sunscreen product in each arm) are absorbed into
      the systemic circulation when a sunscreen product is applied under maximal use conditions.

      One sunscreen product with the highest avobenzone exposure will be selected for the second
      part of the study. If there is no quantifiable exposure of avobenzone for any of the
      sunscreen products, the formulation with the highest oxybenzone exposure will be selected for
      Part 2. In addition, 3 new sunscreen products are included in Part 2.

      Part 2 is an open label, 4-arm study in 48 healthy adult subjects with the primary objective
      to assess the pharmacokinetics of the active components in the selected product from Part 1
      and 3 additional products with a combination of active ingredients (avobenzone, oxybenzone,
      octocrylene, ecamsule homosalate, octisalate and octinoxate as applicable/contained in the
      different products).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1

      Part 1 is an open label, randomized, 4-arm pilot study to evaluate the effects of multiple
      applications of 4 different topical sunscreen formulations in healthy adult subjects. Each
      arm will include 6 subjects (3 male and 3 female) with 1 formulation. A total of 24 subjects
      (12 male and 12 female) from all 4 arms will be admitted to the clinical research unit (CRU)
      on Day 0. On the morning of Days 1 through 4, subjects will receive a topical application of
      the study drug at approximately 0900 hours. The study product will be weighed in advance and
      applied by a qualified person from the study team. Subjects will then receive 3 more topical
      applications on the same day at 2, 4, and 6 hours after the first dose.

      Part 2

      Part 2 is an open label, 4-arm study to evaluate the pharmacokinetics of avobenzone,
      oxybenzone, octocrylene, ecamsule homosalate, octisalate and octinoxate (as applicable in the
      different products) after multiple applications of a topical sunscreen formulation in healthy
      adult subjects. Part 2 will include 48 subjects (24 male and 24 female) and each arm will
      include 12 subjects (6 male and 6 female). One of the formulations in Part 2 will be selected
      based on the plasma exposure data from the pilot study (Part 1). A total of 48 subjects (24
      male and 24 female) will be admitted to the CRU on Day 0. On the morning of Days 1 through 4,
      subjects will receive a topical application of the study product at approximately 0900 hours.
      The study drug will be weighed in advance and applied by a qualified person from the study
      team. Subjects will only receive one application on Day 1. On Days 2, 3 and 4 subjects will
      receive an initial dose and 3 more topical applications on the same day at 2, 4, and 6 hours
      after the first dose.

      Parts 1 and 2

      In both parts, approximately 2 mg of active sunscreen ingredient per 1 cm2 of body surface
      (calculation per method of Dubois) will be evenly applied 4 times per study day (except for a
      one-time application on the first day in part 2) to areas of the body typically exposed to
      the sun: face, ears, neck, torso, arms, and legs (approximately 75% of the body surface
      area). The antecubital areas will be avoided when applying the sunscreen due to potential
      contamination of the sites used for intravenous pharmacokinetic (PK) blood sample collection.
      The topical applications of study drug will be administered with subjects in swim wear to
      simulate real world settings as well as for easy application. In addition to swim wear,
      subjects may wear scrubs in between applications and at other times throughout the day/night.
      Subjects are required to shower each morning after the first PK blood sample collection (and
      before the first dose of the day), but not at other times during the day.

      Blood samples (approximately 10 mL per sample) will be collected for determination of plasma
      concentrations for all active ingredients (avobenzone, oxybenzone, octocrylene, ecamsule,
      homosalate, octisalate and octinoxate, where applicable).

      Safety evaluations will include adverse event (AE) monitoring, vital sign measurements, and
      physical examinations. All AEs reported by the subject or observed by the investigator or
      clinical research unit (CRU) staff will be recorded. Any AE reported after the informed
      consent is signed and before study drug application will be recorded as medical history.

      Subjects will remain in the CRU after admission on Day 0 until the morning of Day 7 following
      completion of scheduled end-of-study activities for Part 1. For Part 2, subjects will undergo
      the same schedule but will return to the clinic for follow-up visits on Days 10, 14 and 21.
      Subjects will then be discharged following completion of End-of-Study activities.

      Subjects are not allowed to use products containing any of these active ingredients from 7
      days before check-in until completion of End-of-Study procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">February 18, 2019</completion_date>
  <primary_completion_date type="Actual">February 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 of the study has 4 parallel arms where 4 different sunscreen products will be studied. Part 2 of the study has 4 parallel arms where 4 sunscreen products (one from Part 1 and 3 new sunscreen products) will be studied.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Avobenzone Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxybenzone Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octocrylene Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ecamsule Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homosalate Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octisalate Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octinoxate Maximum Concentration</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
    <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Systemic Exposure to Sunscreen Ingredients</condition>
  <arm_group>
    <arm_group_label>Part 1: Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Cream
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Spray 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Spray 1
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Spray 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Spray 2
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Aerosol Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Aerosol Spray
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Nonaerosol Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Nonaerosol Spray
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Pump Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Pump Spray
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Cream</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 1: Cream</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Octocrylene</other_name>
    <other_name>Ecamsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Lotion</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 1: Lotion</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Oxybenzone</other_name>
    <other_name>Octocrylene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Spray 1</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 1: Spray 1</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Homosalate</other_name>
    <other_name>Octisalate</other_name>
    <other_name>Octocrylene</other_name>
    <other_name>Oxybenzone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Spray 2</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 1: Spray 2</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Oxybenzone</other_name>
    <other_name>Octocrylene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Lotion</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 2: Lotion</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Oxybenzone</other_name>
    <other_name>Octocrylene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Aerosol Spray</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 2: Aerosol Spray</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Oxybenzone</other_name>
    <other_name>Octocrylene</other_name>
    <other_name>Homosalate</other_name>
    <other_name>Octisalate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Nonaerosol Spray</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 2: Nonaerosol Spray</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Octocrylene</other_name>
    <other_name>Homosalate</other_name>
    <other_name>Octisalate</other_name>
    <other_name>Octinoxate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Pump Spray</intervention_name>
    <description>Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
    <arm_group_label>Part 2: Pump Spray</arm_group_label>
    <other_name>Avobenzone</other_name>
    <other_name>Homosalate</other_name>
    <other_name>Octisalate</other_name>
    <other_name>Octinoxate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects who meet all of the following inclusion criteria will be eligible to participate
        in the study:

          1. Subject signs an institutional review board (IRB) approved written informed consent
             and privacy language as per national regulations (e.g., Health Insurance Portability
             and Accountability Act authorization) before any study related procedures are
             performed.

          2. Subject is a healthy man or woman, 18 to 60 years of age, inclusive, who has a body
             mass index of 18.5 to 29.9 kg/m2, inclusive, at Screening.

          3. Subject has normal medical history findings, clinical laboratory results, vital sign
             measurements, 12 lead electrocardiogram (ECG) results, and physical examination
             findings at Screening or, if abnormal, the abnormality is not considered clinically
             significant (as determined and documented by the investigator or designee).

          4. Subject must have a negative test result for alcohol and drugs of abuse at screening
             and Check-in (Day 0).

          5. Subject has no known or suspected allergies or sensitivities to any components of the
             sunscreen formulation.

          6. Female subjects must be of non-childbearing potential or, if they are of childbearing
             potential, they must: 1) have been strictly abstinent for 1 month before Check in (Day
             0) and agree to remain strictly abstinent for the duration of the study and for at
             least 1 month after the last application of study drug; OR 2) be practicing 2 highly
             effective methods of birth control (as determined by the investigator or designee; one
             of the methods must be a barrier technique) from at least 1 month before Check in (Day
             0) until at least 1 month after the last application of study drug.

          7. Female subjects must not be pregnant or lactating before enrollment in the study.

          8. Male subjects must agree to practice 2 highly effective methods of birth control (as
             determined by the investigator or designee; one of the methods must be a barrier
             technique) from at least 1 month before Check in (Day 0) until at least 1 month after
             the last application of study drug.

          9. Subject is highly likely (as determined by the investigator) to comply with the
             protocol defined procedures and to complete the study.

        Note: subjects with any skin type or skin pigment type may be eligible for the study.

        Subjects who meet any of the following exclusion criteria will not be eligible to
        participate in the study:

          1. Subject has broken, irritated, or unhealed skin.

          2. Subject has an active sunburn.

          3. Subject has used a tanning bed in the previous 4 weeks.

          4. Subject has known skin or autoimmune disease(s).

          5. Subject is anemic or has any chronic condition(s) that may impact blood sample
             collection.

          6. Subject has any underlying disease or surgical or medical condition (e.g., cancer,
             human immunodeficiency virus [HIV], severe hepatic or renal impairment) that could put
             the subject at risk or would normally prevent participation in a clinical study.

          7. Subject has known or suspected allergies or sensitivities to any components of the
             sunscreen formulation.

          8. Subject has clinical laboratory test results (hematology and serum chemistry) at
             Screening that are outside the reference ranges provided by the clinical laboratory
             and considered clinically significant by the investigator.

          9. Subject has a positive test result at Screening for HIV 1 or 2 antibody, hepatitis C
             virus antibodies, or hepatitis B surface antigen.

         10. Subject is unable or unwilling to undergo multiple venipunctures for blood sample
             collection because of poor tolerability or poor venous access.

         11. Subject has received or applied the topical sunscreen formulations used in the current
             study, or any other product containing the active ingredients of the topical sunscreen
             formulations used in the current study, within 7 days before Check in (Day 0).

         12. Subject has used any personal care product(s) containing any active sunscreen
             ingredient, such sunscreen products, hand or body moisturizing lotion, makeup or
             foundation, lip balm, or lipstick, within 7 days before Check in (Day 0).

         13. Subject is unable or unwilling to tolerate the scent of sunscreen for the duration of
             the treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos R Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical Research LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Matta MK, Zusterzeel R, Pilli NR, Patel V, Volpe DA, Florian J, Oh L, Bashaw E, Zineh I, Sanabria C, Kemp S, Godfrey A, Adah S, Coelho S, Wang J, Furlong LA, Ganley C, Michele T, Strauss DG. Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2019 Jun 4;321(21):2082-2091. doi: 10.1001/jama.2019.5586.</citation>
    <PMID>31058986</PMID>
  </results_reference>
  <results_reference>
    <citation>Matta MK, Florian J, Zusterzeel R, Pilli NR, Patel V, Volpe DA, Yang Y, Oh L, Bashaw E, Zineh I, Sanabria C, Kemp S, Godfrey A, Adah S, Coelho S, Wang J, Furlong LA, Ganley C, Michele T, Strauss DG. Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2020 Jan 21;323(3):256-267. doi: 10.1001/jama.2019.20747. Erratum in: JAMA. 2020 Mar 17;323(11):1098.</citation>
    <PMID>31961417</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>April 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2020</results_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunscreen</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Avobenzone</mesh_term>
    <mesh_term>Homosalate</mesh_term>
    <mesh_term>Oxybenzone</mesh_term>
    <mesh_term>2-ethylhexyl salicylate</mesh_term>
    <mesh_term>Octylmethoxycinnamate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data from the clinical study was included as part of supplementary materials for both publications</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Jan 2020 - supplementary materials included with publications</ipd_time_frame>
    <ipd_access_criteria>Access to JAMA. De-identified data has been included under supplement 3 for Part 1 (Matta et al, 2019 JAMA) and Part 2 (Matta et al, 2020, JAMA) of this clinical study
Part 1 study data:
https://cdn.jamanetwork.com/ama/content_public/journal/jama/938034/jpc190002supp3_prod.xlsx</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://jamanetwork.com/journals/jama/fullarticle/2733085</doc_url>
      <doc_comment>Deidentified participant data for Part 1 is accessible under Supplement 3</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://jamanetwork.com/journals/jama/fullarticle/2759002</doc_url>
      <doc_comment>Deidentified participant data for Part 2 is accessible under Supplement 3</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03582215/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03582215/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Equal allocation of men and women for each treatment arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Cream</title>
          <description>Part 1: Cream:
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Lotion</title>
          <description>Part 1: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Spray 1</title>
          <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Spray 2</title>
          <description>Part 1: Spray 2:
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P5">
          <title>Part 2: Lotion</title>
          <description>Part 2: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P6">
          <title>Part 2: Aerosol Spray</title>
          <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P7">
          <title>Part 2: Nonaerosol Spray</title>
          <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Pump Spray</title>
          <description>Part 2: Pump Spray:
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Cream</title>
          <description>Part 1: Cream
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Lotion</title>
          <description>Part 1: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Spray 1</title>
          <description>Part 1: Spray 1
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Spray 2</title>
          <description>Part 1: Spray 2
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B5">
          <title>Part 2: Lotion</title>
          <description>Part 2: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
Part 2: Sunscreen Product #1, 2, 3 or 4: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B6">
          <title>Part 2: Aerosol Spray</title>
          <description>Part 2: Aerosol Spray
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B7">
          <title>Part 2: Nonaerosol Spray</title>
          <description>Part 2: Nonaerosol Spray
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B8">
          <title>Part 2: Pump Spray</title>
          <description>Part 2: Pump Spray
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="10.8"/>
                    <measurement group_id="B2" value="34.5" spread="6.9"/>
                    <measurement group_id="B3" value="42.8" spread="13.0"/>
                    <measurement group_id="B4" value="33.7" spread="9.1"/>
                    <measurement group_id="B5" value="45.1" spread="13.8"/>
                    <measurement group_id="B6" value="41.4" spread="13.4"/>
                    <measurement group_id="B7" value="39.2" spread="12.2"/>
                    <measurement group_id="B8" value="29.0" spread="8.5"/>
                    <measurement group_id="B9" value="37.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="2.8"/>
                    <measurement group_id="B2" value="25.4" spread="2.5"/>
                    <measurement group_id="B3" value="24.1" spread="3.2"/>
                    <measurement group_id="B4" value="24.0" spread="3.0"/>
                    <measurement group_id="B5" value="26.2" spread="2.2"/>
                    <measurement group_id="B6" value="25.8" spread="3.7"/>
                    <measurement group_id="B7" value="25.8" spread="2.4"/>
                    <measurement group_id="B8" value="26.0" spread="3.3"/>
                    <measurement group_id="B9" value="25.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Type I - highly sensitive, always burns, never tans (e.g. Red hair with freckles); Type II - Very sun sensitive, burns easily, tans minimally (e.g. Fair skinned, fair haired Caucasians); Type III - Sun sensitive skin, sometimes burns, slows tans to light brown (e.g. Darker Caucasians); Type IV - Minimally sun sensitive, burns minimally, always tans to moderate brown (e.g. Mediterranean type Caucasians, some Hispanics); Type V - Sun insensitive skin, rarely burns, tans well (e.g. Some Hispanics, some Blacks); and Type VI - Sun insensitive, never burns, deeply pigmented (e.g. Darker Blacks).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="10.4"/>
                    <measurement group_id="B2" value="73.2" spread="17.3"/>
                    <measurement group_id="B3" value="70.9" spread="9.9"/>
                    <measurement group_id="B4" value="69.1" spread="12.5"/>
                    <measurement group_id="B5" value="76.3" spread="10.8"/>
                    <measurement group_id="B6" value="76.0" spread="15.6"/>
                    <measurement group_id="B7" value="72.0" spread="8.9"/>
                    <measurement group_id="B8" value="75.5" spread="12.9"/>
                    <measurement group_id="B9" value="74.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.7" spread="9.9"/>
                    <measurement group_id="B2" value="168.4" spread="15.5"/>
                    <measurement group_id="B3" value="70.9" spread="9.9"/>
                    <measurement group_id="B4" value="171.7" spread="6.0"/>
                    <measurement group_id="B5" value="170.3" spread="9.7"/>
                    <measurement group_id="B6" value="171.0" spread="11.0"/>
                    <measurement group_id="B7" value="167.0" spread="9.3"/>
                    <measurement group_id="B8" value="170.2" spread="11.1"/>
                    <measurement group_id="B9" value="169.8" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body surface area (m^2)</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.2"/>
                    <measurement group_id="B2" value="1.8" spread="0.3"/>
                    <measurement group_id="B3" value="1.8" spread="0.1"/>
                    <measurement group_id="B4" value="1.8" spread="0.2"/>
                    <measurement group_id="B5" value="1.9" spread="0.2"/>
                    <measurement group_id="B6" value="1.9" spread="0.2"/>
                    <measurement group_id="B7" value="1.8" spread="0.2"/>
                    <measurement group_id="B8" value="1.9" spread="0.2"/>
                    <measurement group_id="B9" value="1.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Avobenzone Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Cream</title>
            <description>Part 1: Cream:
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Lotion</title>
            <description>Part 1: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Spray 1</title>
            <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Spray 2</title>
            <description>Part 1: Spray 2:
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Lotion</title>
            <description>Part 2: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Aerosol Spray</title>
            <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Nonaerosol Spray</title>
            <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Pump Spray</title>
            <description>Part 2: Pump Spray:
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Avobenzone Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="32"/>
                    <measurement group_id="O2" value="4.3" spread="46"/>
                    <measurement group_id="O3" value="4.0" spread="61"/>
                    <measurement group_id="O4" value="3.4" spread="77"/>
                    <measurement group_id="O5" value="7.1" spread="74"/>
                    <measurement group_id="O6" value="3.5" spread="71"/>
                    <measurement group_id="O7" value="3.5" spread="73"/>
                    <measurement group_id="O8" value="3.3" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxybenzone Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream and for Part 2, nonaerosol spray and pump spray products did not contain oxybenzone and were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Lotion</title>
            <description>Part 1: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Spray 1</title>
            <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Spray 2</title>
            <description>Part 1: Spray 2:
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Lotion</title>
            <description>Part 2: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Aerosol Spray</title>
            <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Oxybenzone Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream and for Part 2, nonaerosol spray and pump spray products did not contain oxybenzone and were excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.3" spread="45"/>
                    <measurement group_id="O2" value="209.6" spread="67"/>
                    <measurement group_id="O3" value="194.9" spread="52"/>
                    <measurement group_id="O4" value="258.1" spread="53"/>
                    <measurement group_id="O5" value="180.1" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Octocrylene Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 2, pump spray product did not contain octocrylene and was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Cream</title>
            <description>Part 1: Cream:
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Lotion</title>
            <description>Part 1: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Spray 1</title>
            <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Spray 2</title>
            <description>Part 1: Spray 2:
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Lotion</title>
            <description>Part 2: Lotion:
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Aerosol Spray</title>
            <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Nonaerosol Spray</title>
            <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Octocrylene Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 2, pump spray product did not contain octocrylene and was excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="47"/>
                    <measurement group_id="O2" value="5.7" spread="66"/>
                    <measurement group_id="O3" value="2.9" spread="102"/>
                    <measurement group_id="O4" value="7.8" spread="113"/>
                    <measurement group_id="O5" value="7.8" spread="87"/>
                    <measurement group_id="O6" value="6.6" spread="78"/>
                    <measurement group_id="O7" value="6.6" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ecamsule Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, lotion, spray 1, and spray 2 and for Part 2, lotion, aerosol spray, nonaerosol spray, and pump spray did not contain ecamsule and were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Cream</title>
            <description>Part 1: Cream:
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Ecamsule Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, lotion, spray 1, and spray 2 and for Part 2, lotion, aerosol spray, nonaerosol spray, and pump spray did not contain ecamsule and were excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homosalate Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream, lotion, and spray 2 and for Part 2, lotion did not contain homosalate and were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Spray 1</title>
            <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Aerosol Spray</title>
            <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Nonaerosol Spray</title>
            <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Pump Spray</title>
            <description>Part 2: Pump Spray:
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Homosalate Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream, lotion, and spray 2 and for Part 2, lotion did not contain homosalate and were excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="74"/>
                    <measurement group_id="O2" value="23.1" spread="68"/>
                    <measurement group_id="O3" value="17.9" spread="62"/>
                    <measurement group_id="O4" value="13.9" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Octisalate Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream, lotion, and spray 2 and for Part 2, lotion did not contain octisalate and were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Spray 1</title>
            <description>Part 1: Spray 1:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Aerosol Spray</title>
            <description>Part 2: Aerosol Spray:
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Nonaerosol Spray</title>
            <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Pump Spray</title>
            <description>Part 2: Pump Spray:
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Octisalate Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, cream, lotion, and spray 2 and for Part 2, lotion did not contain octisalate and were excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="46"/>
                    <measurement group_id="O2" value="5.1" spread="82"/>
                    <measurement group_id="O3" value="5.8" spread="77"/>
                    <measurement group_id="O4" value="4.6" spread="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Octinoxate Maximum Concentration</title>
        <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2</time_frame>
        <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, octinoxate was not analyzed for cream, lotion, spray 1, and spray 2 and all products were excluded from the analysis. For Part 2, lotion and aerosol spray did not contain octinoxate and were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Nonaerosol Spray</title>
            <description>Part 2: Nonaerosol Spray:
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Pump Spray</title>
            <description>Part 2: Pump Spray:
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
          </group>
        </group_list>
        <measure>
          <title>Octinoxate Maximum Concentration</title>
          <description>Maximum concentration (observed peak drug concentration) (Cmax)</description>
          <population>All subjects who received at least one application and had at least one pharmacokinetic sample. For Part 1, octinoxate was not analyzed for cream, lotion, spray 1, and spray 2 and all products were excluded from the analysis. For Part 2, lotion and aerosol spray did not contain octinoxate and were excluded from the analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="87"/>
                    <measurement group_id="O2" value="5.2" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days for part 1; 21 days for part 2</time_frame>
      <desc>MedDRA</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Cream</title>
          <description>Part 1: Cream
Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Lotion</title>
          <description>Part 1: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Spray 1</title>
          <description>Part 1: Spray 1
Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Spray 2</title>
          <description>Part 1: Spray 2
Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E5">
          <title>Part 2: Lotion</title>
          <description>Part 2: Lotion
Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Aerosol Spray</title>
          <description>Part 2: Aerosol Spray
Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Nonaerosol Spray</title>
          <description>Part 2: Nonaerosol Spray
Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Pump Spray</title>
          <description>Part 2: Pump Spray
Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye burning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abodinal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel punctue site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" events="11" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" events="7" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was conducted in indoor conditions and was not designed to assess differences by formulation or participant factors.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Strauss, MD, PhD</name_or_title>
      <organization>U.S. Food and Drug Administration</organization>
      <phone>301-796-6323</phone>
      <email>David.strauss@fda.hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

